TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05422911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study: NCT05085457

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ExPreS Protocol
Description: Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
Study: NCT05707234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRH
Description: The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam sedation
Description: During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Description: During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
Study: NCT06659523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPS supplement intervention
Description: 31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
Study: NCT06602921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TruBeet inorganic beetroot juice
Description: 400 mg nitrate-rich beetroot powder, mixed with 300 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TruBeet inorganic beetroot juice
Description: 400 mg nitrate-rich beetroot powder, mixed with 300 mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 6 mg/kg caffeine powder in capsule form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 6 mg/kg caffeine powder in capsule form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: 3 min cold pressor test using the left foot in cold water (0-2 degree).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold pressor test
Description: 3 min cold pressor test using the left foot in cold water (0-2 degree).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold pressor test
Description: 3 min cold pressor test using the left foot in cold water (0-2 degree).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold pressor test
Description: 3 min cold pressor test using the left foot in cold water (0-2 degree).
Study: NCT05946018

Intervention type: OTHER
Group type: OTHER
Intervention: Educational video on ergonomics
Description: A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational video on ergonomics
Description: A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Verbal physical therapy coaching sessions
Description: Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
Study: NCT05909189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEADing Dementia End-of-Life Planning Conversations
Description: The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
Study: NCT06074250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: 1500mg EPA +1000mg DHA daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: 1500mg EPA +1000mg DHA daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: 1500mg EPA +1000mg DHA daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination strain of lactobacillus and bifidobacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination strain of lactobacillus and bifidobacteria

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: Dietary consult with follow-up to ensure target fiber intake is met.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Quality
Description: one time dietary consult at enrollment to discuss strategies to improve overall diet.
Study: NCT06186388

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TEMPO iMOvifa
Description: Screening test with 28 testing points

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TEMPO iMOvifa
Description: Screening test with 28 testing points
Study: NCT05937035

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Customized allogenic bone block surgery
Description: After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
Study: NCT04721327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote CI programming
Description: provision of CI programming provided remotely via Zoom in a 2 hour session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote CI programming
Description: provision of CI programming provided remotely via Zoom in a 2 hour session
Study: NCT05991778

Intervention type: DEVICE
Intervention: Bioelectrical impedance vector analysis (BIVA)
Description: BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.

Intervention type: DEVICE
Intervention: Bioelectrical impedance vector analysis (BIVA)
Description: BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine analysis
Description: For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine analysis
Description: For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.

Intervention type: DIAGNOSTIC_TEST
Intervention: cumulative water balance
Description: Cumulative balance is the sum of daily fluid balances during hospitalization.
Study: NCT05773105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+regorafenib
Description: cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
Study: NCT06065163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diuretic de/escalation based on ultrasound findings (VExUS Score)
Description: Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
Study: NCT05991778

Intervention type: DIAGNOSTIC_TEST
Intervention: cumulative water balance
Description: Cumulative balance is the sum of daily fluid balances during hospitalization.
Study: NCT05988593

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: consume one bottle (30 mL) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MelaGene+
Description: consume one bottle (30 mL) per day
Study: NCT04709029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravenous
Description: Evaluation of intravenous dexamethazone in prevention of postdural puncture headache

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intrathecal
Description: Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
Study: NCT05569421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: BGF MDI HFO
Description: Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: BGF MDI HFO
Description: Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: BGF MDI HFA
Description: Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: BGF MDI HFA
Description: Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
Study: NCT06541912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant
Description: A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV implant
Description: A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures.
Study: NCT06537102

Intervention type: OTHER
Group type: OTHER
Intervention: Unilateral laparoscopic ovarian drilling
Description: Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary.

Intervention type: OTHER
Group type: OTHER
Intervention: Bilateral laparoscopic ovarian drilling
Description: Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume.
Study: NCT05942131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based laughter yoga
Description: A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks.
Study: NCT06430307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saussurea Involucrata Liquid Tonic
Description: This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saussurea Involucrata Liquid Tonic
Description: This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
Study: NCT06309121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic ABB C3
Description: A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up Postbiotic ABB C3 (Optional)
Description: Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-up Postbiotic ABB C3 (Optional)
Description: Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
Study: NCT06360679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric restriction and biliodigestive diversion
Description: The BariTon™ is endoscopically implanted and retrieved once treatment is completed
Study: NCT05496101

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative CLI + FAR LightPath imaging
Description: Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical
Study: NCT06463847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials.
Study: NCT05814341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate
Description: Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citrate
Description: Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
Study: NCT06197139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-XT117
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.